Gilder Gagnon Howe & Co’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,657	Closed	-$2.42M	–	286
2023 Q4	$2.42M	Sell	7,657 -265	-3%	-$51.5K	0.03%	173
2023 Q3	$1.34M	Buy	7,922 +30	+0.4%	+$5.64K	0.02%	197
2023 Q2	$1.71M	Buy	7,892 +552	+8%	+$118K	0.02%	202
2023 Q1	$1.33M	Sell	7,340 -231	-3%	-$44.2K	0.02%	188
2022 Q4	$1.49M	Sell	7,571 -58	-0.8%	-$12.4K	0.03%	184
2022 Q3	$1.72M	Buy	+7,629	New	+$1.54M	0.03%	177
2020 Q1	–	Sell	-9,002	Closed	-$678K	–	307
2019 Q4	$678K	Buy	+9,002	New	+$394K	0.01%	237

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Gilder Gagnon Howe & Co's KRTX Position: Q1 2024 in Review

Gilder Gagnon Howe & Co sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 7,657 shares — an estimated $2.42M sold.

Gilder Gagnon Howe & Co first reported a position in KRTX in Q4 2019 and held it in 7 quarters. The position peaked at $2.42M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Gilder Gagnon Howe & Co reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 7,657 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.42M.
Gilder Gagnon Howe & Co first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
Gilder Gagnon Howe & Co's Karuna Therapeutics, Inc. Common Stock position peaked at $2.42M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2024, filed 15 May 2024.